Universities and colleges own the discoveries they make with federal research funding thanks to the Bayh-Dole Act. Since it passed in 1980, commercialized innovations from federally funded research have contributed trillions of dollars to the U.S. economy, according to the Bayh-Dole Coalition. Some of the discoveries made possible by the Bayh-Dole Act include Google’s search engine, tests for cervical cancer, lithium car battery recycling and high-definition video and audio.

In this episode of The Key, IHE’s editor in chief, Sara Custer, speaks with Joe Allen, the executive director of the Bayh-Dole Coalition, to understand the origins of the legislation and how it could be upended by changes to policies governing research funding.

 

Follow us on Apple Podcasts Spotify

Thank you to our episode sponsor Grammarly. 

A lockup logo for Grammarly
View Transcript

Note: Transcripts may be created with the help of automated tools and lightly edited for clarity.

Transcript

Sara Custer: Hello and welcome to The Key. I’m Sara Custer, editor in chief at Inside Higher Ed. Here’s a little quiz for you. What do Google, firefighting drones and the nicotine patch all have in common? Well, they were made possible by the Bayh-Dole Act, a piece of bipartisan legislation written by Birch Bayh, a Democratic senator from Indiana, and Bob Dole, a Republican senator from Kansas. The act lets universities, nonprofits and small businesses keep ownership of inventions they create with federal research funding. At a time when that funding is under pressure, I wanted to speak with Joe Allen, the executive director of the Bayh-Dole Coalition, to understand the origins of the legislation and how it could be impacted by the current uncertainty around research funding. Joe was a staffer on the Senate Judiciary Committee to Senator Bayh and helped pass the act in 1980. The coalition he now leads is a group of research institutions and university tech transfer offices, venture capital and small business groups, and economic development organizations. They lobby for the act as well as issues related to tech transfer. Far from perfect, the legislation has enabled federally funded research discoveries to move out of university labs and into the real world. In our conversation, Joe explains how the Bayh-Dole Act sets America apart from our research competitors and why political interference from either side could put the whole thing at risk.

Sara Custer: Thanks to Grammarly for sponsoring this episode. For nearly 20 years, Grammarly has been the writing partner that over 3,000 higher education communities trust, helping students, faculty and staff communicate with clarity, confidence, and integrity. Now, as part of Superhuman, that legacy grows, expanding from writing support into new agentic capabilities, giving institutions more ways to help their people write, learn and work. Grammarly is built for institutions and loved by students worldwide. Learn more at grammarly.com/edu.

Sara Custer: Hi, Joe. Welcome to The Key.

Joe Allen: Well, thank you for inviting me. I’m looking forward to talking with you.

Sara Custer: Joe, we’re going to talk with you today about your work at the Bayh-Dole Consortium and even before that, your work on actually getting this piece of legislation passed in Congress. And it’s all about tech transfer and how institutions can work with private organizations to really get their research out into the public to serve that public good for taxpayer-funded research. Before we get into that, Joe, though, we are on the key. So I have to ask you: tell me about a time when you’ve lost your keys.

Sound clip: Where are my keys?

Joe Allen: Well, I haven’t lost my keys, but I’ve come close to losing my mind a couple of times. And then that could happen. That could happen at any moment now. But about 15 years ago, I actually started my own consulting business. And I live in a little town called Bethesda, Ohio. I’m actually from Washington, D.C., but I’m out in rural Ohio, which I really love. So I was just starting, and some friends of mine at the National Institutes of Health, which is in Bethesda, Maryland, had a group from Africa, which is touring the world trying to figure out how to get African universities more involved in the economy, which was great. And they wanted to talk to me. And of course, seeing Bethesda, they assumed that I was right next door. So we actually wound up doing a, this is before Zoom calls, wound up doing a phone call. I talked to them about the Bayh-Dole Act, which we’ll talk about now and how it gets universities involved, blah, blah, blah. So that was fine. So about six months later, I get an email from Africa asking if I would come over there. And I was like, oh, I guess. You know, if you’ll pay my way, I’ll do it. But this is when, this is when, if you’re, if you’ve been on the internet long enough, this is when the first scams were starting. And one of the first scams I ever saw, which looked very serious the first time you saw it, was the famous prince from Nigeria who was trying to move money out of the country and just got your email from some reliable person and said, Hey, if you’ll let me put money in your bank account, I’ll give you 50%. Do you remember that? So anyway, I get this email from these people in Africa, which I’ve never met before, never seen before, saying, We’d like you to come over here and speak. We want to reimburse you, but we’ll need a copy of your Social Security number, your bank account number and your passport number. So I’m like, okay, this sounds like I want to jump right into. And they want me to come to Cape Town. So I was kind of ambiguous about it, but one of my friends who’d been there said, oh, man, you’ll love it. Cape Town’s like San Francisco. You know, I really wanted to help. This was South Africa. We had Nelson Mandela’s party, which had overthrown apartheid, trying to do something to get the economy working. So I thought, okay, I’ll go. So I agree to go. Well, flying from the United States to Africa, when you get to Africa, you’re halfway there. So it’s a 17-hour flight. And we were actually delayed. So I got to meet all the people on the plane. So if you’ve ever flown that far, you know what you feel like when you stumble off the airplane. So, whatever day it was, I’m stumbling off the airplane, met this guy I’ve never met before, and I think I’m going over there to talk to some African universities. So I’ve got this little, you know, rote speech there. So as I come off the plane, he says, okay, thanks for coming over here. We’ll pick you up at eight o’clock tomorrow morning. You’re speaking to our parliament. That’s the first time I had any idea. But what are you going to do? I mean, I’m not going to get back on the plane and go back again. So it actually turned out to be great. I mean, the South African parliament is really based on the English Parliament. So if you’ve ever seen, you know, the Prime Minister questions, you got these two benches there facing each other and you got one bench there. And it was really cool, but it was one of those things where, you know, you’ve jumped into something, you don’t know anybody there, you’ve never been there before. You think you’re going to there for some routine thing. And the next thing you know, you’re talking to their parliament. But it actually turned out to be great. They couldn’t have been nicer to me. I had a great time there. But it’s just one of those times where you’re way over your skis. And they’re all wearing robes. I mean, it really was like, it really was like you’re in the English parliament, but you’re in South. So it turned out well, but it’s one of those things where, you know, again, I did wasn’t robbed. It was legitimate, but you’re thinking, what in the world have I gotten into?

Sara Custer: But still not what you expected.

Joe Allen: No, and you can imagine how much you slept that night after you’ve been on the plane for 17 hours and was you got to be up at eight o’clock in the morning to go speak to the parliament.

Sara Custer: But sure. Probably a lot of revising of that presentation and the speech that you had prepared for the university.

Joe Allen: No, actually, there wasn’t. I was too tired and too stupid to do anything. So I thought, this is it. You know, either like it or not. I mean, this is what you’re going to get. And it’s funny because just like our parliament, they weren’t listening to me as much as talking to each other. I would say something. And then one of them, I mean, I had nothing about South African parliaments, but the Bozi, I mean, the two sides are opposite sides. So I would make a statement and somebody would interrupt me and then turn to one of their colleagues and sort of throw it in their face again. So I was kind of like the person in the middle as a bullets are flying back and forth. But they did enact the Bayh-Dole Act. I actually worked with them on the implementing regulations. It’s my first only trip to South Africa, but it turned out well. But it’s one of those things, again, where you stumble off the plane and think, I would have rather lost my keys than being over there for 38 hours.

Sara Custer: Having that dropped in your lap.

Joe Allen: And having that dropped in my lap. But again, you know, you deal with what you deal with, and it actually turned out to be fine.

Sara Custer: Sounds like it. So one, just roll back quickly. What are the Bethesda connections? Did they think that you were in some way connected with the NIH?

Joe Allen: Well, yeah, I mean, but if Bethesda, Ohio, Bethesda, Maryland is where NIH. So people see Bethesda and assume, well, you know, you’ve got to be in Maryland. Bethesda, Ohio couldn’t be further away than Bethesda, Maryland in every sense of the word. So we’re like a tiny little town, you know, one store, one gas station. I mean, I’m from D.C., so I know Bethesda, Maryland very well. But, you know, if you’re a consultant, you’re not telling people, hey, I live out in rural Ohio and I can’t do something.

Sara Custer: So do you just kind of let Bethesda hang there? Like, oh, yeah, I live in Bethesda, depending on who you’re talking with. I see.

Joe Allen: Right. Well, we don’t get many people going through Bethesda, Ohio looking for technology.

Sara Custer: Well, great story, Joe. Thank you so much for sharing that.

Sound clip: Dude, where are my keys?

Sara Custer: Tell us a little bit about the Bayh-Dole Consortium for people who might never have heard of it. Who are your members? What do y’all do?

Joe Allen: Well, basically, I was on Senator Birch Bayh’s staff. Senator Bayh was a Democrat from Indiana, and I was on a Senate Judiciary Committee staff, and we passed the law, which we’ll talk about in a little bit. So basically, what’s happening is the Bayh-Dole Act is one of the things that undergirds the U.S. economy and innovation. But very few people have heard about it. And it kind of works invisibly. It’s like the little engine they could. It works every day, doesn’t ask for anything, doesn’t take any federal dollars, just keeps producing. But what we found was that a lot of people just either take it for granted, don’t know anything about it and have no idea how our system works. So about five years ago, a number of us said right before COVID hit, you know, we need to really explain to policymakers, the media and the public how this law works because there are people, for good or bad, trying to undermine it or go some other direction. And so there was really nobody defending it. So we started a little organization. It was like a little club. And we said, you know, we’ll have a program and explain to people how Bayh-Dole works. It was the 30th anniversary of the law. Then COVID hit. So you couldn’t do meetings. So what happened was we started doing a couple of things and people liked it. So it evolved into actually a nonprofit organization. Our website is Bayh, B-A-Y-H, Dole, D-O-L-E, coalition.org. And our members are basically people that have a stake in either producing federal research or commercializing it. So if you look on our website, you’ll find we have small business members, we have the National Association of Manufacturers, a Chamber of Commerce, we have a number of universities, we have industry people, and really our stakeholders of the public and private sector who all work together to bring federally funded inventions to the market and just want to make sure people understand how important this is, that we should never take it for granted. And that’s really what we do. So we try to explain how the law works. We just put out a new survey about the economic impact. We actually have the original documents on the development of why the federal government funds research going back to World War II to today. So people really get a sense of this is how the system works. And it’s actually one of the things that’s actually made American competitive. It’s one of our leading-edge tools to compete with China. So we want to make sure people understand that because if you get it wrong, the consequences really are significant.

Sara Custer: And I think it’s fascinating that this piece of legislation was bipartisan. As you said, it was with Senators Bayh and Senators Dole working across the aisle there. And in today’s political terms, that just seems impossible. So I’m curious if how you feel having been a huge part of this legislation being passed and being a part of writing it and shepherding it, how does that feel to you now, having worked for this very important bipartisan piece of legislation and then kind of seeing how politics works now?

Joe Allen: Well, it wasn’t that different then because, again, I was a young staffer on Senator Bayh’s staff. He was up for reelection in 1980. Senator Dole was a Republican, and he was one of the leaders of the Republican Party. So it’s kind of like being on a professional sports team. You know, you play hard, but you know who the people are on the other side that you respect. And on Capitol Hill, they say there’s two kinds of members: there’s workhorses and show horses. So, workhorses are the people that are serious, that you can do business with and get things on. The show horses are people out there, you know, playing for the media. Bayh and Dole were both workhorses. So, even though they opposed each other on most things, I mean, they were, you know, they were leaders of their parties going into a political year, but they also were pragmatic. And what we found was that before the Bayh-Dole Act, the government was funding billions of dollars with a B of research, but it wasn’t being commercialized. And we were shocked to find out that not a single drug had been developed from all these billions of dollars of NIH funding because there was no incentives for anybody to actually develop them. So, I and Birch Bayh heard about that, we got really interested in it. And we found out that Senator Dole actually was interested in the same thing. So, we reached out to his staff and said, Hey, we’d like to work together on this. They said, Great. And I think it was a magic combo. It would be almost like in today’s world if Ted Cruz and Elizabeth Warren decided to work together on something, you know. And I think the fact was that Bayh and Dole were so respected that people took it seriously. But also, we had a great issue because at that time, the economy was much, much worse off than it is now. In the 1970s, it really looked like America’s days were over. We had double-digit inflation and double-digit unemployment. We have nothing like that now. I mean, you know, people are happy now, but people were really unhappy then. And the other thing was we’d lost key markets that we dominated for 40 years. We’d lost electronics, we’d lost steel, we lost automotive. And a lot of experts were saying it was inevitable the U.S. was in decline. That, you know, we were not number one. We were looking like we would be number three or four. So I think politically, people were shocked. The American public was angry as they could be. And we said, okay, we don’t agree on everything, but we can’t afford to squander billions of dollars of taxpayer-funded research and just give it away to our foreign competitors. So it was a long, hard fight to get it across. We barely got it finalized. But it really does show the American system operates if you have serious people looking at serious problems and actually have a pragmatic approach to it, which I think both sides appreciated. You know, it wasn’t like we were, it wasn’t some philosophical thing. We said, look, we’ve got to get a system that works. The bottom line is everyone suffers. No one’s benefiting if this stuff isn’t commercialized. I mean, do you want to have a cancer drug or do you want to have a paper? That’s what we’re talking about.

Sara Custer: And I think it’s important to underline that for anybody who wasn’t working in research pre-Bayh-Dole, that’s what would happen: there would be these discoveries, it would be published in research, it would be put out there in the world, and then it would just kind of go in a journal and sit there. And it would belong to the federal government and it wasn’t going out there to be commercialized or used by the public.

Joe Allen: It was actually worse than that because there were consumers of it. The Japanese bought, took all of our tech, all of our publications. The government’s publishing things all the time. Nothing wrong with publication. But if you don’t patent it, it’s not going to be developed here. So what happened was the Japanese went through our federal laboratories and our universities all the time looking for cutting-edge research and say, well, how would this work? How would this work in biotech? And again, it’s not sabotage. We’re giving it away. So they knew more about our research than we did. And what they would do is they would go back to Japan, share notes, and say, okay, how do we put this to application to develop a product? So while we’re not making the United States, we’re giving away our best and brightest ideas to our foreign competitors. And again, you can’t blame them. I mean, if we’re dumb enough to give it away, you can’t blame them for recognizing the value of it. And that made, you know, once we raised that, that made people in Congress crazy. I mean, it would be even, you know, if one thing is just publishing it, but the other thing is now you’re giving it to your economic competitors who are taking markets away from you. And they were very thankful for it. So, it was one of those policies that I think everybody on both sides of the aisle said: wait a minute, we may not agree on a whole bunch. We’re in an election year. And Dole, you know, Dole was campaigning against Birch Bayh for re-election. So, this is not like people think there was this kumbaya. No, we’re agreeing on this one issue. These are two rival teams. You know, you respect the people on the other side who play the game right, but you’re still playing for your team. So, you know, Bayh-Dole was an exception. But I think back to your point, it really does show the American system can operate if you have serious people looking at a serious issue and coming up with something that really is pragmatic. You know, not dogma, it’s pragmatic.

Sara Custer: It still has had its critics, though, among modern politicians and from both sides of the aisle. So, President Biden tried to enact what’s called march-in rights to try to lower drug costs. And then we also had last year, Commerce Secretary Howard Lutnick proposing a 50% tax on some of the royalties that universities receive from licensing those patented discoveries. How are you feeling about how politicians are seeing it now?

Joe Allen: Well, let me just correct on one thing. We actually have, again, there are people that don’t like Bayh-Dole. There are people that want to go back to the previous system that really do believe sincerely that if you give technology away, if you put it in the public domain, it’ll be commercialized and it’ll be cheaper. Now, there’s no evidence to show that works. We have evidence to show, but again, that’s a philosophical belief that the taxpayers paid for something, people shouldn’t be making money off of it, it should be in the public domain. And debate that later. So, Senator Biden actually, when he was a senator, actually supported Bayh-Dole. The Biden administration and the Obama administration were being pressured by people who don’t like Bayh-Dole to misuse the law to say that if you commercialize a product based on federally funded research, the government can mandate the price. That if people don’t think the price is reasonable, quote unquote, with no definition, after you’ve made it, then they can license your competitors. And we came back, and Senator Bayh and Dole said, no, no, no, that’s not how the law worked. So there were petitions filed to try to misuse the law for price control, but both the Obama administration and the Biden administration, and actually every other administration has turned those down. So Senator President Biden never tried to march in. I think philosophically, people were, you know, because a lot of progressives were supporting it, but they realized when you’re running the administration, they knew from talking to NIH that would destroy their programs. Because NIH knew if you try to play this kind of game and you’re going to pose price controls after somebody’s taken all the risks. And remember, a drug cost at least $2 billion to develop over 10 years. So we’re not, it’s not a lot of small risk. No one’s going to do that if after you’ve developed it, somebody says, I don’t like the price, it’s not reasonable. And there’s no definition of that. So they all said, once they got to the edge, they said, wait a minute, this doesn’t make any sense. So every administration since 1980, the Reagan administration, Obama administration, conservative Bush administration, they’ve all supported Bayh-Dole. But again, there are people still pushing that theory. Back to Secretary Lutnick’s idea. He did float that. Again, under Bayh-Dole, universities get royalties back if something’s been commercialized. You know, they get to get money back. And we can talk about that. So Secretary Lutnick just said one time: okay, if they’re getting this much money back, the government should take half of it because we funded the research. That’s not how the law works. And to his credit, I think once he kind of threw the idea out there, once they actually did some homework on it, you realize that, first of all, that’s not section under Bayh-Dole. But if they did that, it would cost the government more money than they’re making right now because when people commercialize a new product, they pay taxes on it. So the government’s getting much more money from taxing successfully commercialized than they would ever make from taking university royalties. So I think that’s one of the reasons we started the Bayh-Dole Coalition: when these questions come up, we try not to be ideological. We try to go back and say, okay, here’s how the law works, and here’s the consequences of doing what you’re talking about. Now, you can decide whether you want to do that or not, but I think in fairness with Secretary Lutnick and the Commerce Department, once they saw what that would actually do, it would actually undermine innovation and actually cost the government money. They backed off of that. So both of those are examples of people raising, you know, good faith reasons. I’m not attacking your motivation. But once you look into both those ideas about the government imposing price controls or the government just taking half the money, it may sound good on the surface, but in reality, it would do much more harm than it would do good.

Sara Custer: Okay. We might circle back to the philosophical concerns that people have about what commercializing research does. But I did just want to throw a figure out there that I think from your consortium’s own economic outlook report, maybe outlook isn’t the right word, economic study about tech transfer and what it’s contributed to economic output in the United States. And I believe that the number between 1996 and 2025 was $3.3 trillion in economic output across the United States. And that is going to universities as well as small businesses as well as to entrepreneurs.

Joe Allen: Well, no, that’s going to the U.S. economy. Okay, so here’s what we’re looking at. We said, okay, universities license an invention and it gets commercialized. What’s the impact of that on the U.S. economy? So, as you said, for 30 years from 1996 to 2025, it contributed $3.3 trillion with a T to the U.S. economy, but that didn’t go back to the universities. The universities make about $3.2 billion with a B a year on royalties. So, the multiplier is: you have the universities have an early stage invention. Somebody starts a company, they put money into that. Typically, a company will invest $100 for every $1 the government put into the research because development’s the expensive part. They do that at their own risk. When they have the product there, they start hiring people, they start manufacturing it. That’s where the economic multiplier comes in. And we also showed in our study the impact of every state. So, the $3.3 trillion is what the U.S. taxpayers are getting back. As we talked about, Secretary Lutnick, the government’s taking taxes on that $3.3 trillion, which is much more money. The Bayh-Dole Act was not designed to enrich universities that doesn’t. But it’s saying, okay, if the government’s funding this research, we want to make sure it’s commercialized, both to help improve the health and safety of the United States and also to help the economy. So that’s what it’s doing. But again, universities are making a small percentage of that. I mean, a lot of times, universities will license something at a 2% or 5% royalty. So for every $98 being sold, you’re getting $2 back. That’s the difference.

Sara Custer: Thank you. Thank you for explaining that. And that goes into my next question, which there have been studies showing that a lot of times tech transfer doesn’t even cover the costs of a lot of these risks that universities are taking to make these discoveries. So would you say universities often lose money on tech transfer?

Joe Allen: Well, again, let’s go back and define it. Tech transfer is a service on campus. Okay, it’s not a profit-making center. And if you look at the Bayh-Dole Act, again, the law mandates how, again, royalties come back, you’ve licensed a product, and now it’s being sold. So it’s been commercialized. And you’ll have a licensing deal. So the university will say, okay, I get 2% back of your sales as royalties. When that money comes in, Congress said, Bayh and Dole said, okay, the first thing you have to do is reward your inventors because university inventors are not paid to patent. Patenting is a whole thing beyond their job description. So typically, universities will pay 25 to 30% of the royalties off the top to the inventors. We also said that you can recover your costs because the government does not pay the patenting costs, doesn’t pay the tech transfer costs, and the rest of the money goes back into funding research. So, typically, the tech transfer office will get a small percentage of what they license back there. There’s more money going on campus. And again, every once in a while, you’ll have a giant hit like Google. I mean, Google came out of a small grant. Stanford built a new research center. I mean, you’ve had the University of Pennsylvania build new research facilities, but that money goes back into funding more research. It’s a virtuous cycle. So, a lot of times universities will get started on tech transfer, but again, it’s a service to the faculty, and it also helps the federal agencies justify their budgets because once these things are commercialized, you have to report your inventions back to the agency that funded it. Well, the reason that you and I are having this Zoom call today and we can see each other and people can take a picture on your cell phone is because of research that NASA funded, the Jet Propulsion Lab. And the inventor had the crazy idea of what if you could take a picture through your cell phone. There was no market for that. No one had ever thought about that. No one saw a need for it. But he started his own company with his wife. And that’s why we’re able, that’s why we have, we can see each other on Zoom calls now. So that’s what you want federally funded research to do: find those other applications. The government did not pay for that. The government didn’t take any risk for that. And Google, Stanford couldn’t license Google. Nobody wanted it. There already were search engines. So two kids said we want to start a company. Well, how much money is the government made from taxing Google? But again, that’s really how our system operates. So without the incentives of the Bayh-Dole Act, those things would just be laying there. No one would see the application of it. But again, the purpose of Bayh-Dole is to help the American taxpayer, the American public. We have no problem with universities making money from royalties when that happens, but that’s really not the intent of the law.

Sara Custer: So you mentioned Google. I’ve got another list here of some other products, things, let’s say, for lack of a better term, that have come out of university research, mRNA technology, the mRNA technology behind COVID-19 vaccines. Our listeners probably are aware of that. Also, firefighting drones and also mobile cloud computing systems are a few things that I’ve got on my list of inventions that have changed lives, saving lives that have come out to us as a result of the Bayh-Dole legislation. I wanted to ask, when we’re talking about, because this is so related to federal research funding, as we know, there are pressures on federal research funding right now. The White House is trying to restrict that funding. Thankfully, Congress has pushed back on those proposals, but we’re also seeing some funding agencies slow-walking grants out. A lot of grants have been canceled due to executive orders against anti-DEI and various, frankly, arbitrary reasons. How is your coalition thinking about that? Are you concerned about the pressures on federal funding?

Joe Allen: Yeah, and I think that’s a great question. Every once in a while, the U.S., this is actually the first time since World War II that people have actually looked at systematically: okay, what’s the return on investment to the American taxpayer for funding $60 billion of academic research? What are we getting back for that? There’s nothing wrong with that. That’s a lot of money, and people need to have an answer for that. That’s one of the reasons we did our study. So we need to explain to people: okay, what are you getting back for that thing? And remember, the government’s funding research for two purposes. And this goes back to Vannevar Bush back in 1944, when President Roosevelt said, we’ve never funded civilian research before. What do we do with this? And Vannevar Bush said in Science, the Endless Frontier that funding fundamental research, which should be a purpose of the federal government, industry’s not going to do that. It’s too high risk. It’s too special. So the government funds fundamental research and it also funds mission research. Like I mentioned, NASA funded a thing at the Jet Propulsion Lab looking for a small camera to go into space. They had no idea about cell phones. So that’s what the government’s doing. What we’re trying to do is explain to people that because of the Bayh-Dole Act, those investments are being turned into real-world products. You mentioned some FluMist, the nicotine patch, supermarket barcodes, immunotherapy, which won a Nobel Prize for new cancer treatment, all came out of Bayh-Dole, a lot of it out of fundamental research. So our concern is, you know, there’s nothing wrong with asking those questions. But what people need to understand is it’s companies that take the risk of commercialization, not the federal government. And under our system, 70% of university and federal laboratory licenses go to small companies. The inventor of the cell phone technology, he started his own company with his wife and their house. So, you know, that’s really what drives U.S. innovation. People won’t do that unless they understand what the rules are. And so if there’s uncertainty about what the government’s going to do, particularly funding research or arbitrarily stopping research, that has a real impact. Again, I have no problem making sure the government’s funding good science. It shouldn’t be ideological science on either side. It should be good science. But when Congress appropriates money, people bid on that, remember the government’s putting out these bids. We want to have research on this topic. So it’s not like people are just making stuff up. If you go through the process and you win that, you should get the grant or the contract. I mean, again, this is the government. The government’s controlling all this. The government tells you we’re putting a grant out or a contract out for this much money to do this. And so that’s not being forced on them. Again, nothing wrong with looking at, does this make sense? Is this something that’s worthwhile? But our process works. It’s working in the hard, cold light of day under both Republican and Democratic administrations. And if it looks like people are playing political games on either side, that’s when people lose confidence. Because remember, these small companies are betting Eric Fossum and his wife bet their house on their new company. No one guarantees success. It would not have done that if it looked like people are going to change the rules after that started. The other thing is, you know, you’re not going to have the top, some of the top minds in the world, not just the United States, working in the public sector if there’s no predictability to the government’s going to continue funding this research. I mean, that’s why you’re in the public sector. You like doing research. You could make more money in industry, but you like doing things which an industry wouldn’t be allowed to do. That’s why you’re there. But you still have to pay the bills. So if it looks like every six months, you have to wonder if your funding is going to come through or, you know, are they going to whatever, whatever, if there’s some arbitrary thing there, people understand if I’m not doing good science, you shouldn’t get funded. People understand that. If this research doesn’t go anywhere, okay, maybe we’re funding something else. But if you’re just going to say a political appointee or a bureaucrat can just say, I don’t like you or whatever, whatever reason, I don’t want to fund this. That’s where the system falls apart. So, that’s the real danger. There’s nothing wrong with asking hard questions, nothing wrong with demanding accountability. We’re all big boys and girls. If you’re going to play in the system and get that kind of money, you should be accountable. But if you’re playing by the rules and you’re doing what the government said, you should not be playing, you should not be having people arbitrarily looking at, you know, we’re going to now have a political angle to it. And that could be on either side. And the other thing is, you know, once one side does it, once you set that precedent up, okay, what’s going to happen when the other side gets out? So that’s what people need to understand. I mean, there really are implications to this. I mean, once you start establishing a precedent in government, it’s not just there for your side, it’s there for the other side too. And so that’s the real danger. Again, you know, some of this is beyond the scope of the Bayh-Dole Coalition. Right. All I’m saying is: look, the rules have to be predictable. The rules have to be enforced fairly. If you do that, we’re having a huge benefit back to the American public. And if you don’t believe that, the Chinese are adopting the Bayh-Dole system to compete with us. So if you don’t believe me, believe the Chinese because they’re adopting best practices. But I went to South Africa because South Africa said this is a best practice.

Sara Custer: So I’m curious to know, as much as you can tell me, how that message lands when you’re talking to lawmakers who maybe do support some of the rule-changing, let’s call it, that’s been happening with federal research funding. You’ve mentioned the economic output that tech transfer brings to the country. You’ve mentioned China, which to a lot of people is our enemy number one in some aspects. You’ve mentioned a lot of different arguments that I would think would land with some of those people. What’s been the response whenever you bring that to them?

Joe Allen: I’ve really been very pleased with that. I’m glad you raised that because when we first started the Bayh-Dole Coalition, when I heard from the reporters, it was mainly coming from the angle: you know, this is a ripoff of the public. It’s charging too much. You know, why are you doing this? It’s enriching people. We don’t get that anymore because we’ve, and this is not just the Bayh-Dole Coalition, but we’ve really tried to pride ourselves in giving people realistic, pragmatic answers to a specific question. If you agree with us or not, we can document what we’re saying. We can show you for this. This report is actually an underestimate because Bayh-Dole also includes federal laboratories and small companies, which are not included on that $3.3 trillion. So, this is an underestimate of the impact. I’d much rather underestimate than have all these pie-in-the-sky things, which people just can’t believe. The other thing we did was for the first time, we broke down the impact by state. So I can show, or we can show any member of Congress, this is what it’s doing to North Carolina. This is what it’s doing to Vermont. This is what it’s doing to your region. And what we found is most members of Congress, again, we’ve got show horses and workhorses. The show horses, you know, there’s not much you can do with them. I mean, they’re out there trying to get the quick hit on the internet. But most serious legislators on both sides of the aisle really want to do the right thing. People are not looking to do something stupid just because it may get them, you know, instant notice, particularly if it’s going to hurt their state. So I’ve been very pleased with the response we’ve gotten because, you know, we really can show people, first of all, there’s a 45-year history of Bayh-Dole. It’s not a fly-by-night thing. These are real numbers. This is a real, we can show you the products. You can quantify this. So a lot of times what people are hitting with is our theories. Okay. Well, anybody can have a theory. That’s fine. Nothing wrong with that. But is there any data to show your theory works? And I think that’s where we can say: look, we’re not attacking people personally. We don’t do that. But we can demonstrate that government price control, NIH tried that under political pressure 20 years ago. What happened? Did it lower prices? No, what happened was industry walked away. And the NIH director said, the only impact of this program, trying to force price control, is we’ve lost valuable partnerships and it’s hurt the American public. We’re going to repeal that system. That’s not me saying that. There were five years of data showing that rather than driving down prices, companies said, I’m walking. Again, we really can’t show that before Bayh-Dole, you had these things put in the public domain. Nothing was being commercialized because, again, in real life, as opposed to theory, some company has to say, okay, I’m going to develop this thing and see if we can put a have the cell phone take a picture. That’s high risk. You mentioned mRNA. Kati Karikó, we actually gave her an award. Her research was so high risk, even the government would not fund it. She was downgraded at the university because she couldn’t bring any funding in because her idea was so high risk. Immunotherapy, which won the Nobel Prize. It took the University of California 10 years to find a licensee. It revolutionized cancer treatment. But at the time it came out, it was so speculative and so different that no company was going to touch it. And they finally found a small company to license it after 10 years. And you mentioned about universities losing money. We actually gave an award out to the woman who licensed mRNA. She was under pressure from the university, not because they’re mean, but the university is saying, why are we spending money on this patent when we can’t license it? But she believed so much in Jim Allison, who was the scientist behind it. She said, no, this is really important. Because of her persistence, this won a Nobel Prize. But easily they could have pulled the plug and said, okay, look, we appreciate what you’re doing. It’s not working. Nobody wants it. It’s been 10 years now. Why are we paying these patent fees? That’s how the system operates. There’s somebody looking at the public benefit. And again, the University of California, once it hit, made a lot of money off the royalties, which went back into building a new research center. So that’s what happened when it hit. But again, but for that research person, but for Kati Karikó, this would never happen. And the final thing is: you know, people forget about this. When Moderna licensed mRNA, they made no money for 10 years, 10 years with no money. They finally hit when the COVID vaccine came, but their real research purpose was cancer. Three weeks ago, the Wall Street Journal said, because of using mRNA, it looks like Moderna has a breakthrough in treating melanoma cancer for high-risk patients, for patients with really bad melanoma. This is a serious disease. That’s how the system operates. But a lot of times, what seems like a fly-by-night success story took 10 years of somebody’s life with no guarantee it was ever going to work. And again, that’s what makes the American system different than China. That’s what American entrepreneurs are about. But it’s really based on the rules are predictable. I’m taking a risk now, but don’t make that risk any harder. Under our system, it’s namely small companies taking that risk. Like these two kids at Stanford who said, okay, nobody wants this. Let’s start a company. We’ll call it Google. It doesn’t happen all the day, but it happened. It does happen.

Sara Custer: And I think because this is based on fundamental research, which is so pie in the sky, and that’s what’s wonderful about it happening in universities, because we know that private companies are never going to allow researchers to just do that, to explore, but it’s so important. But very, very few of those actually end up turning into some sort of patent that institutions could license. Now, it might lead to it in 20 years because somebody bases their research on that, on their research. But it’s very, it’s kind of, if I understand it correctly, it’s kind of needle in a haystack opportunity whenever those patent opportunities come up.

Joe Allen: Well, again, it all depends on the technology you’re looking at, but it does happen. And it’s not like one of them big. I mean, again, we had, our study showed more than 19,000 companies have been started in the last 25 years in university technologies. I mean, we’re starting three new companies and commercializing two new technologies on average every day of the year. It’s happening. But again, it’s not to be taken for granted. And each one of those, if you look at it, there’s an entrepreneur in the public sector and the private sector who are risking their careers and their livelihood on having it, it’s, they’re not, it’s not, it’s not welfare. No one’s handing you this, you know, because the government has a patent. There’s no guarantee it’s going to make money, but that’s the genius of the American system, is we have entrepreneurs like Kati Karikó, who are willing to stake their personal careers on this, and we have people like Eric Fossum and his wife, who are willing to put their houses up to say, I believe in this enough. I’m going to put my house on the line. I mean, that’s really sincere. But again, those are the kind of people that drive our economy. And I think back to your question, everybody relates to that. I mean, that’s why on a bipartisan basis, when we actually have a thing, the Bayh-Dole Coalition has a thing called the Faces of American Innovation, where we tell the stories of people like Kati Karikó and Eric Fossum and Jim Allison. So people really understand you should never take this for granted. It was not a given immunotherapy would ever be developed. It was not a given mRNA or any of these things. There’s not a given these things are going to happen. And they’re happening here, not other places, because of our system. You know, the United States is by far still the most innovative country in the world. We’re having the best and brightest come here because you have economic freedom and political freedom, which you’re not going to get in China. So we want to make sure we don’t undermine that system.

Sara Custer: Let me ask you just about kind of where this goes in light of some of the stressors and uncertainty around federal research funding. And a lot of people are trying to look for some alternatives. And maybe research funding, maybe these research projects end up being a combination of federal funding, some philanthropy, maybe a state fund, maybe even some industry funds. Maybe it ends up being a bit more of a patchwork than it is now. What happens to Bayh-Dole in that sort of situation?

Joe Allen: Well, that’s happening now. I mean, again, if you look at it, it all depends on the different project, but it’s not unusual to have industry funding research at universities. They fund about 10% as much as the federal government. So it’s much smaller. The way the Bayh-Dole Act works is if there’s federal funding in there, you’re falling under the provisions of Bayh-Dole. And that’s not really owners, but what it’s making sure of is that there’s an incentive there for the university and their inventors to commercialize the technology. And the other thing the law says is you have to give a preference when you’re licensing to a small company or somebody who’s going to make it in the U.S. So we really want to make sure to the extent we can, the economic benefits stay here. But if you can’t do that, you can make it somewhere else. So those provisions still stay there. Now, again, if it’s completely funded by industry or somebody else, it’s not Bayh-Dole. I think, again, if you look at the economic benefits of it, the Bayh-Dole system operates because what we’ve done is we’ve aligned the incentives for the public and private sector. So everyone wins if it’s commercialized. And that’s critical. John Preston, who’s one of the people that started the MIT licensing office, said passion is the most important ingredient to commercialization. That if the inventor, if the institution and the company don’t have the same passion, it’s not going to work. And that’s really true. So, again, we don’t guarantee success. A lot of times people fail. A lot of times people lose money. But the incentives for success are aligned under Bayh-Dole. And if you start messing with that alignment, if you take the inventor out of it or the institution out of it, or make it harder for the company or the VC, remember there’s a VC there who’s, that’s their own money, not government money. And you’re betting, okay, I’m going to get a return from this. It may take you 10 years, but you’re betting on these small companies to come up with something that the big guys can’t do, or you’re gonna sell it to the big guys. Nothing wrong with that. But that’s what we need people to understand on both sides of the aisle. This is not welfare, it’s not a given, it’s not magic. But the Bayh-Dole Act works. And the other thing I’ll say about it is: the Bayh-Dole Act didn’t create any bureaucracy. The Bayh-Dole Act doesn’t cost the government an extra dime. What you’re doing is you’re leveraging research that’s already being done and having industry drive it now to come up with other benefits, which, I mean, it’s literally true because of Bayh-Dole, there’s millions of people alive today that wouldn’t be otherwise. People are walking. If you look at TV now, you’ll find things for HIV back, HIV, for treating AIDS. 15 years ago, AIDS was a death knell. In fact, I worked with some of the scientists at San Francisco at the VA laboratory there who were one of the first people who saw AIDS patients. And within six, 12 months, they were dead. People now are living with AIDS, even in Africa. I mean, that’s a miracle. It’s a miracle. Not just because of Bayh-Dole, it’s because of Bayh-Dole working with companies. But one of the key ingredients for the AIDS cocktail came out of Emory University. We actually gave that person an award. That’s how the system operates. So it’s not just for making money, nothing wrong with making money. But the motivation of Birch Bayh and Bob Dole was: we want the American people to be better off, and we want people around the world to be better off. Because again, the U.S. is leading in all these areas. And I’d much rather have us be the leader in things like that, particularly have a humanitarian impact, than China. China’s not noted for going into disaster areas and giving people stuff for free. We were the ones, we produced so much COVID vaccine. It was actually wasting away in the third world because they actually couldn’t utilize it quick enough, you know, and for the demand. We did that. Not anybody else. If China, I mean, I don’t want to speculate on what China would do, but I don’t know too many people who want to rely on China when there’s a world pandemic. I sure don’t.

Sara Custer: Joe, thank you so much for coming on and explaining, hopefully to our listeners, a little bit more about Bayh-Dole and how this has impacted tech transfer and really made tech transfer possible for the United States. Thank you so much.

Joe Allen: Well, thank you. I enjoyed talking with you.

Sara Custer: Thanks to Grammarly for sponsoring this episode. For nearly 20 years, Grammarly has been the writing partner that over 3,000 higher education communities trust, helping students, faculty and staff communicate with clarity, confidence, and integrity. Now, as part of Superhuman, that legacy grows, expanding from writing support into new agentic capabilities, giving institutions more ways to help their people write, learn and work. Grammarly is built for institutions and loved by students worldwide. Learn more at grammarly.com/edu.

Share This Article